SCHEMBL348314

SCHEMBL348314

O=Cc1cccc(C(=O)O)c1O

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ERN1 O75460 5/20 0.57
ALDH1A1 P00352 4/20 0.53
KDM4E B2RXH2 2/20 0.53
HPGD P15428 2/20 0.53
ALB P02768 1/20 0.53
HSD17B10 Q99714 1/20 0.53
MMP2 P08253 1/20 0.53
HNF4A P41235 1/20 0.50
TLR2 O60603 1/20 0.48
TLR1 Q15399 1/20 0.48
TLR6 Q9Y2C9 1/20 0.48
ALOX15 P16050 1/20 0.46
HMGB1 P09429 2/20 0.46
TRIM24 O15164 1/20 0.45
TRIM33 Q9UPN9 1/20 0.45
CA12 O43570 1/20 0.45
CA1 P00915 1/20 0.45
CA2 P00918 1/20 0.45
CA4 P22748 1/20 0.45
CA6 P23280 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29357851 1.00 ERN1 (0.57) ERN1ALDH1A1KDM4EHPGDALB
Water SCHEMBL17627596 0.98 ERN1 (0.55) ERN1ALDH1A1KDM4EHPGDALB
Ethylenediamine SCHEMBL29021645 0.91 HMGB1 (0.56) ERN1ALDH1A1KDM4EHPGDALB
SCHEMBL28725539 0.84 HMGB1 (0.45) ERN1ALDH1A1KDM4EHPGDALB
SCHEMBL8120539 0.83 ERN1 (0.57) ERN1ALDH1A1KDM4EHPGDHSD17B10
SCHEMBL8611275 0.82 ALDH1A1 (0.53) ALDH1A1KDM4EHPGDALBHSD17B10
SCHEMBL29444101 0.82 ALDH1A1 (0.52) ALDH1A1KDM4EHPGDALBHSD17B10
SCHEMBL29953417 0.82 ERN1 (0.55) ERN1ALDH1A1KDM4EHPGDHSD17B10
Hydrochloric Acid SCHEMBL29912876 0.82 ERN1 (0.55) ERN1ALDH1A1KDM4EHPGDHSD17B10
SCHEMBL5463687 0.82 ALDH1A1 (0.52) ALDH1A1KDM4EHPGDALBHSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 188 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260069594-A1 USE OF AN AGENT CAPABLE OF INHIBITING THE ACTIVATION OF MAIT CELLS FOR THE TREATMENT OF RHEUMATOID ARTHRITIS INST NAT SANTE RECH MED (FR) 2026-03-12 US claimed
EP-4580611-A1 USE OF AN AGENT CAPABLE OF INHIBITING THE ACTIVATION OF MAIT CELLS FOR THE TREATMENT OF RHEUMATOID ARTHRITIS Institut National de la Santé et de la Recherche Médicale (FR) 2025-07-09 EP claimed
CN-120115188-A Vanadium-based catalyst, preparation method thereof and application thereof in catalyzing oxidation of 5-hydroxymethylfurfural to prepare 2, 5-diformylfuran 中国科学院大连化学物理研究所 2025-06-10 CN claimed
US-20240076303-A1 Green Synthesis of Salicylaldehydate-Metal-Organic Frameworks and Applications Thereof Khalifa University of Science and Technology (AE) 2024-03-07 US claimed
WO-2024047196-A1 USE OF AN AGENT CAPABLE OF INHIBITING THE ACTIVATION OF MAIT CELLS FOR THE TREATMENT OF RHEUMATOID ARTHRITIS Institut National de la Santé et de la Recherche Médicale (FR) 2024-03-07 WO claimed
CN-115931829-A Method for separating and measuring coloring metal elements in ultra-white glass 中国洛阳浮法玻璃集团有限责任公司 2023-04-07 CN claimed
US-20220184083-A1 USE OF AN AGENT CAPABLE OF INHIBITING THE ACTIVATION OF MAIT CELLS FOR THE TREATMENT OF OBESITY AND OBESITY-RELATED DISORDERS CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR) 2022-06-16 US claimed
EP-3941448-A1 USE OF AN AGENT CAPABLE OF INHIBITING THE ACTIVATION OF MAIT CELLS FOR THE TREATMENT OF OBESITY AND OBESITY-RELATED DISORDERS Institut National de la Santé et de la Recherche Médicale (INSERM) (FR) 2022-01-26 EP claimed
US-20210403573-A1 METHODS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF FIBROSIS WITH AGENTS CAPABLE OF INHIBITING THE ACTIVATION OF MUCOSAL-ASSOCIATED INVARIANT T (MAIT) CELLS UNIVERSITÉ PARIS CITÉ (FR) 2021-12-30 US claimed
WO-2020187955-A1 USE OF AN AGENT CAPABLE OF INHIBITING THE ACTIVATION OF MAIT CELLS FOR THE TREATMENT OF OBESITY AND OBESITY-RELATED DISORDERS INSERM (Institut National de la Santé et de la Recherche Médicale) (FR) 2020-09-24 WO claimed
WO-2020080957-A1 METHODS OF TREATING OR PREVENTING SKIN CONDITIONS MALCORP BIODISCOVERIES LIMITED (NZ) 2020-04-23 WO claimed
CN-107417930-B A kind of biomass acid material and preparation method thereof 南京汉旗新材料科技有限公司 2019-11-05 CN claimed
CN-110098443-A A kind of method of carbon coating waste lithium cell negative electrode material 浙江卡波恩新材料有限公司 2019-08-06 CN claimed
CN-109777398-A A kind of polychrome tunable radiation emitting composite material of N doping carbon dots coordination rare earth and its polychrome light altering film for agriculture of preparation 山东农业大学 2019-05-21 CN claimed
WO-2018234843-A1 METHODS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF FIBROSIS WITH AGENTS CAPABLE OF INHIBITING THE ACTIVATION OF MUCOSAL-ASSOCIATED INVARIANT T (MAIT) CELLS INSERM (Institut National de la Santé et de la Recherche Médicale) (FR) 2018-12-27 WO claimed
CN-107417930-A A kind of biomass acid material and preparation method thereof 南京汉旗新材料科技有限公司 2017-12-01 CN claimed
CN-105154069-A Multi-colored adjustable light-emitting material of nitrogen-doped carbon dot coordination rare earth and preparation method thereof UNIV SHANDONG AGRICULTURE 2015-12-16 CN claimed
CN-103467766-B Rapid preparation method of totally-biodegradable composite membrane with nanometer silver on surface UNIV ZHEJIANG SCIENCE & TECH 2015-03-18 CN claimed
CN-103467766-A Rapid preparation method of totally-biodegradable composite membrane with nanometer silver on surface UNIV ZHEJIANG SCIENCE & TECH 2013-12-25 CN claimed
US-4424346-A Derivatives of chitins, chitosans and other polysaccharides CANADIAN PATENTS AND DEVELOPMENT LTD. (CA) 1984-01-03 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260069594-A1 USE OF AN AGENT CAPABLE OF INHIBITING THE ACTIVATION OF MAIT CELLS FOR THE TREATMENT OF RHEUMATOID ARTHRITIS MIF, MTX1, PTGS1 ERN1 4655/4885ALDH1A1 407/4885KDM4E 2194/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.